文献速递心力衰竭与心肌病

急性心衰住院期间体重下降作为成功减容的标志

Weight loss as a marker of successful decongestion during acute heart failure hospitalisation.
PubMed 文献 · Heart · 2026-09-03

在瑞典心衰注册研究中,4979例接受静脉袢利尿剂治疗的急性心衰住院患者中,59%实现体重下降≥2 kg;体重下降与30天内再住院心衰风险降低(HR 0.59)及心血管死亡或再住院心衰复合终点风险降低(HR 0.76)独立相关,且此关联不受生物标志物变化影响。

要点

  • 静脉利尿剂所致体重下降≥2 kg与30天内再住院心衰风险降低独立相关(HR 0.59)。
  • 体重下降与30天内心血管死亡或再住院心衰复合终点风险降低独立相关(HR 0.76)。
  • 体重下降的获益独立于生物标志物变化,包括肾功能恶化。

核心结论

  • 急性心衰住院期间利尿剂所致体重下降是成功减容的实用标志,与短期临床结局改善相关且不伴随肾功能下降。

研究设计与样本

  • 基于瑞典心衰注册研究(2017-2021)的全国性队列,纳入4979例接受静脉袢利尿剂、存活出院且有入院和出院体重的急性心衰住院患者。

主要发现

  • 住院期间中位体重变化为-2.5 kg,2949例(59%)实现体重下降≥2 kg。
  • 体重下降与30天内再住院心衰风险降低独立相关(HR 0.59,95%CI 0.53-0.67)。
  • 体重下降与30天内心血管死亡或再住院心衰复合终点风险降低独立相关(HR 0.76,95%CI 0.69-0.84),但30天后无此关联。
  • 体重变化与eGFR变化无有意义的关联。
  • 关联在不同生物标志物变化(包括肾功能恶化)中一致。

临床怎么用

  • 可将住院期间体重下降≥2 kg作为急性心衰减容成功的实用监测指标。
  • 体重下降带来的短期获益不受肾功能恶化等生物标志物变化影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Effective decongestion is a key therapeutic goal during hospitalisation for acute heart failure (HF), but the clinical significance of intravenous loop diuretic-induced weight loss and its relationship with biomarker changes remain uncertain. METHODS: We included patients hospitalised for HF in the nationwide Swedish Heart Failure Registry (2017-2021) who received intravenous loop diuretics, survived to discharge and had body weight recorded at admission and discharge. Weight loss was defined as ≥2 kg between admission and discharge. Associations between weight loss, changes in biomarkers (estimated glomerular filtration rate (eGFR), N-terminal pro-B-type natriuretic peptides (NT-proBNP), haemoglobin, sodium and potassium) and outcomes were evaluated. The primary outcome was rehospitalisation for HF (re-HHF); the secondary outcome was the composite of cardiovascular death or re-HHF at 30 days and 1 year. RESULTS: Among 4979 patients (median age 80 years; 57% male), median weight change during hospitalisation was -2.5 kg and 2949 (59%) achieved weight loss ≥2 kg. Male sex, atrial fibrillation, obesity, higher admission NT-proBNP and mineralocorticoid receptor antagonist use were independently associated with weight loss. Weight change showed no meaningful association with change in eGFR. Weight loss was independently associated with a lower risk of re-HHF (HR 0.59, 95% CI 0.53 to 0.67) and the composite of cardiovascular death or re-HHF (HR 0.76, 95% CI 0.69 to 0.84) within 30 days but not thereafter. These associations were consistent irrespective of biomarker changes, including worsening renal function. CONCLUSIONS: In this nationwide cohort of patients hospitalised for HF and treated with intravenous loop diuretics, diuretic-induced weight loss, a pragmatic marker of decongestion, was associated with improved short-term clinical outcomes without an accompanying decline in renal function and irrespective of biomarker changes, including worsening renal function.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Erhardsson, Lund, Benson, et al. Weight loss as a marker of successful decongestion during acute heart failure hospitalisation. Heart. 2026. PMID: 42642074. doi:10.1136/heartjnl-2026-328175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。